Recent Advances in Clinical Application of Gut Hormones  by Tseng, Ping-Huei et al.
J Formos Med Assoc | 2010 • Vol 109 • No 12 859
Contents lists available at ScienceDirect
Journal of the Formosan Medical Association
Journal homepage: http://www.jfma-online.com
J Formos Med Assoc 2010;109(12):859–861
Journal of the 
Formosan Medical Association
ISSN 0929 6646
Formosan Medical Association
Taipei, Taiwan
Volume 109 Number 12 December 2010
Recent advances in clinical application of gut hormones
Urinary NGF levels in OAB and lower urinary tract disorders
Pollen allergy in Taiwanese patients
Parvovirus infection among hospital staff
News and Perspectives
Recent Advances in Clinical Application of 
Gut Hormones
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Many peptide hormones that are synthesized and
secreted from the gastrointestinal (GI) tract have
been discovered. Gut hormones play an important
role in regulation of food intake, GI motility, en-
ergy balance and body weight by working with the
complex neural circuits in the brainstem, hypo-
thalamus and higher cortical centers. Recent intro-
duction of bariatric surgery for treatment of type 2
diabetes in overweight patients further highlights
the differential effects of gut hormones on the en-
teroinsular axis and glycemic control. In addition,
another promising anti-obesity strategy is to attain
a negative energy balance through manipulation
of the circulating gut hormones as well as their tar-
get receptors. In this article, the basic physiology
of several peptide hormones associated with GI
motility disorders, obesity and diabetes is re-
viewed, and advances in the clinical application
of gut hormones are discussed (Table).
Ghrelin and GI Motility Disorders
Ghrelin is an endogenous ligand for the growth
hormone secretagogue receptor, and is secreted
mostly by the X/A-like cells in the gastric fundus.
Ghrelin is currently the only orexigenic gut 
hormone to promote food intake and accelerate
gastric emptying. Therefore, ghrelin and its analogs
have been used in patients with anorexia or mal-
nutrition. For example, Ashby et al showed that
malnourished dialysis patients can achieve a sus-
tained positive energy balance by daily ghrelin
treatment.1
Circulating ghrelin levels have been reported
to be lower in patients with functional dyspepsia
which implies a therapeutic role of ghrelin and
related compounds. For example, repeated admin-
istration of ghrelin can stimulate appetite in pa-
tients with functional dyspepsia.2 In addition,
ghrelin accelerates gastric emptying in patients
with diabetic gastroparesis. A synthetic, selective
ghrelin receptor agonist, TZP-101, is well-tolerated
and effective for diabetic gastroparesis and post-
operative ileus after partial colectomy.3,4 Therefore,
analogs of ghrelin could represent a new class of
prokinetic agents in the future.
Pancreatic Polypeptide-fold Peptides,
Amylin and Obesity
Pancreatic polypeptide-fold peptides consist of two
gut hormones: peptide YY (PYY) and pancreatic
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polypeptide (PP). PYY is released from L-cells of
the distal gut into the circulation. PP is secreted
from F-cells in the pancreas and the colon. Amylin
is co-released with insulin from pancreatic β cells
and has a similar physiological profile to insulin.
PYY 3-36 (the predominant circulating form of
PYY), PP and amylin increase satiety, reduce food
intake, delay gastric emptying and regulate energy
expenditure. As a result, these hormones could
be of benefit to weight control and obesity treat-
ment. In human studies, obese subjects have been
found to have low levels of PP and PYY. In addi-
tion, chronic PYY treatment in mice enhances in-
sulin sensitivity, and promotes insulin-mediated
glucose disposal. Intravenous PP infusion reduces
food intake in healthy people and patients with
Prader–Willi syndrome, who have a deficiency in
basal and meal-stimulated circulating PP levels
and present with dramatic hyperphagia and mor-
bid obesity. In obese mice, repeated adminis-
tration of PP has been shown to decrease body
weight gain and ameliorate insulin resistance and
hyperlipidemia.5
It has been reported that the combination of
amylin and PYY 3-36 has greater anorexigenic
and weight-reducing effects than either peptide
alone.6 Concurrent administration of amylin
and leptin can induce synergistic weight loss in
leptin-resistant, diet-induced obese rats. In patients
with obesity and type 2 diabetes, administration
of pramlintide, a synthetic analog of human
amylin, has been shown to improve glycemic
control and cause weight loss. Furthermore, in 
a 24-week randomized, double-blind study, co-
administration of pramlintide and recombinant
human leptin elicited a mean weight loss of 12.7%
in overweight/obese subjects.7
Glucagon-like Peptide 1 (GLP-1) and
Diabetes
GLP-1 belongs to a family of incretins that stim-
ulate insulin secretion in a glucose-dependent
manner. GLP-1 promotes glucose sensitivity and
insulin biosynthesis and inhibits glucagon release.
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In addition, GLP-1 delays gastric emptying and
decreases appetite and body weight.
Previous studies have indicated that patients
with type 2 diabetes have decreased plasma con-
centrations of GLP-1, and continuous subcuta-
neous administration of GLP-1 greatly improves
glucose profiles and lowers body weight and he-
moglobin A1c levels.8 However, GLP-1 is rapidly
inactivated by dipeptidyl-peptidase 4 (DPP-4).
Accordingly, several GLP-1 analogs or DPP-4 in-
hibitors have been developed to treat diabetes.
Exenatide (exendin-4), a DPP-4-resistant GLP-1
receptor agonist and sitagliptin, a DPP-4 inhibitor,
have been shown to reduce food intake and body
weight, and thus improve glycemic control in pa-
tients with type 2 diabetes. In metformin-treated
type 2 diabetes patients, exenatide has a greater
effect than sitagliptin to increase insulin secre-
tion and reduce postprandial glucagon secretion
and glucose levels.9 Another long-acting human
GLP-1 analog, liraglutide, also improves glycemic
control and is well tolerated.10
Conclusion and Future Perspective
In summary, gut hormones help to regulate ap-
petite and GI motility and maintain body energy
homeostasis. With a marked expansion of knowl-
edge about the structure and pathophysiology of
gut hormones, various new drugs have been de-
veloped with remarkable efficacy and tolerance
on the basis of natural peptides and their agonists
or antagonists. Such pharmacological approaches
could shed light on the management of obesity,
diabetes, and GI motility disorders in the fore-
seeable future. Further investigations are war-
ranted to optimize the route of administration,
dosing and drug combination, and to minimize
the adverse effects of these new agents in our
clinical practice.
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